Synthetic Biology and Biotech Defence in Europe, 2026–2030
Medical countermeasures, biosurveillance and dual-use manufacturing in Europe’s emerging security architecture.
19 pages · PDF · 23 May 2026 · Licensed single-user copy, watermarked to the buyer
Strategic Biotechnology, Human Enhancement & MedTech Synthetic Biology
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Synthetic biology and biotech defence are becoming central to Europe’s security agenda because biological risk can no longer be treated only as a public-health issue. Pandemics, deliberate biological release, CBRN incidents, antimicrobial resistance, contested logistics and critical-medicine shortages now form part of the same strategic environment.
The European response remains fragmented across health security, defence R&D, export controls, stockpiling, surveillance, industrial policy and treaty compliance, but the direction is clear: biotechnology is becoming a regulated defence-adjacent infrastructure, where value depends not only on scientific capability but also on preparedness,…
Key questions this report answers
- Why are synthetic biology and biotech defence becoming central to Europe's security agenda across pandemics, deliberate biological release, CBRN incidents, antimicrobial resistance and critical-medicine shortages?
- What legal, institutional and programmatic architecture governs biotech defence?
- What industrial and technological architecture underpins biotechnology as regulated defence-adjacent infrastructure?
- What implications follow for defence finance, industrial policy, M&A, banks and law firms over 2026-2030?
Inside this report
- Executive summary
- Strategic problem
- Legal, institutional and programmatic architecture
- Industrial and technological architecture
- Implications for defence finance, industrial policy, M&A, banks, law firms and D
Who it's for
Strategy, corporate-development and investment teams that need an ecosystem-level view — budgets, industrial capacity and technology landscapes — before committing capital or capacity.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (23 May 2026). You receive a 19-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Strategic reports · Biotechnology, Human Enhancement & MedTech · Synthetic Biology · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →